SynthesisJournal of the American Heart Association2026
Pharmacological and Genetic Targeting of Inflammatory Chemokine Receptors CCR1, CCR2, and CCR5 in Atherosclerosis: A Systematic Review and Meta-Analysis of Preclinical Studies.
Synthesis in Journal of the American Heart Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Harnessing macrophage signaling pathways and scalable engineering for next-generation immunotherapies.Signal transduction and targeted therapy · 2026Review
- Monocyte Chemokines Enhance Atherosclerotic Plaque Necrosis After Bacterial Kidney Infection.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInflammatory chemokine receptors encompassing CCR1, CCR2, CCR3, and CCR5 orchestrate the recruitment of leukocytes during inflammation. In atherosclerosis, there is ongoing controversy surrounding the precise role each inflammatory chemokine receptor plays in the disease process. We thus performed a systematic review and meta-analysis to examine the effects of inflammatory chemokine receptor inhibition on experimental atherosclerotic burden.
methodsWe performed a systematic literature search of PubMed/MEDLINE, Embase, and Web of Science for studies on the pharmacological and/or genetic manipulation of inflammatory chemokine receptors in murine models of atherosclerosis or hyperlipidemia. We extracted data on lesion size and morphological composition as primary outcomes, and plasma lipid profile and mouse body weight as secondary outcomes. We used a random effects model to calculate the pooled effect size across studies as the standardized mean difference (SMD) with 95% CIs.
resultsA total of 38 studies of experimental atherosclerosis (CCR1: n=9, CCR2: n=24, CCR5: n=13) were included. Genetic or pharmacological inhibition of CCR2 and CCR5 significantly reduced lesion size (CCR2: SMD=-1.14 [95% CI, -1.47 to -0.81]; CCR5: SMD=-1.06 [95% CI, -1.64 to -0.48]), (CCR2: SMD=-0.72 [95% CI, -1.15 to -0.29]; CCR5: SMD=-1.92 [95% CI, -2.58 to -1.26]) and macrophage load (CCR2: SMD=-1.35 [95% CI, -1.97 to -0.74], CCR5: SMD=-1.29 [95% CI, -2.39 to -0.20]), (CCR2: SMD=-0.86 [95% CI, -1.43 to -0.29]; CCR5: SMD=-1.69 [95% CI, -2.69 to -0.69]), respectively. Pharmacological (but not genetic) targeting of CCR1 significantly reduced lesion size, with protection observed only in males when both approaches were considered.
conclusionsOur analysis suggests that inhibition of either CCR2 or CCR5 is protective in experimental atherosclerosis, while the effect of CCR1 intervention is less clear with potential beneficial effects in male populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.